Bavarian Nordic (OTCMKTS:BVNRY) Shares Gap Up – Should You Buy?

Bavarian Nordic (OTCMKTS:BVNRY)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $10.93, but opened at $11.4350. Bavarian Nordic shares last traded at $11.4350, with a volume of 253 shares trading hands.

Bavarian Nordic Price Performance

The company has a market capitalization of $2.72 billion, a price-to-earnings ratio of 11.56 and a beta of 1.20. The stock has a 50 day simple moving average of $9.63 and a two-hundred day simple moving average of $9.74.

Bavarian Nordic (OTCMKTS:BVNRY) last released its quarterly earnings data on Friday, August 21st. The company reported $0.46 earnings per share (EPS) for the quarter. Bavarian Nordic had a return on equity of 12.06% and a net margin of 24.36%.The business had revenue of $316.47 million during the quarter.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.